Estudo comparativo de gel de palquetas home made versus hidrocolóide no processo de cicatrização de úlcera crônicas de etiologia venosa

As úlceras venosas são impactantes e representam um grande desafio médico devido ao entrelaçamento de comorbidades e causas multifatoriais, sendo de suma importância o surgimento de inovações tecnológicas na abordagem terapêutica que sejam acessíveis aos seus portadores. Diante dessa realidade, este trabalho se propôs a abordar as úlceras venosas comparando um produto existente no mercado, Hidrocolóide (HC), com uma proposta in house, o Gel de Plaquetas (GP), através da diminuição da área, avaliação descritiva da vascularização e queixas referidas. Participaram do estudo 17 pacientes, perfazendo um total de 22 úlceras venosas que foram acompanhados durante 90 dias, utilizando um dos produtos citados, de acordo com o randomização, em associação com o uso de faixas elásticas. A distribuição do grupo, segundo a randomização foi de 13 lesões no grupo de hidrocolóide e 9 no grupo de gel de plaquetas. A média percentual de redução das áreas das feridas foi de 57,78% para hidrocolóide e de 53,45% para gel de plaquetas, não apresentando diferenças estatisticamente significativas. O desempenho dos produtos estudados apresentaram grande similaridade no percentual de redução de área, o que indica que é preciso um estudo amostral maior para evidenciar superioridade de um produto sobre o outro. Porém quando comparados, quanto ao menor tempo de acompanhamento (D15), o gel de plaquetas apresentou melhor desempenho, com redução maior do que o hidrocolóide em tempo reduzido semelhante. A análise histológica no momento pré e pós tratamento sugere que o GP atua de forma a estimular a regeneração dos tecidos (estroma coeso) e de forma mais definitiva (distribuição dos vasos difusa na derme reticular). O aspecto do fechamento da lesão é mais consistente quando comparado com os pacientes que usaram HC onde se observou a formação de uma fina epiderme frágil...Venous ulcers are striking and represent a major challenge due to the commingling of medical comorbidities and multifactorial causes, with the emergence of great importance to technological innovations in therapeutic approaches that are accessible to their patients. Given this reality, this study proposes to address venous ulcers comparing a product on the market, hydrocolloid (HC) with a proposed in-house, the Platelet Gel (GP), by decreasing the area and descriptive evaluation of vascularization complaints referred. The study included 17 patients, a total of 22 venous ulcers who were followed for 90 days, using one of the products listed, according to the randomization, in association with the use of compression elastic. The distribution of the group, according to randomization was 13 injuries in the hydrocolloid group and 9 in the group of platelet gel. The average percentage reduction of wound areas was 57.78% for hydrocolloid and 53.45% for platelet gel, showing no statistically significant differences. The performance of the products studied showed great similarity in the percentage of area reduction, which indicates that it is necessary to study a larger sample to demonstrate the superiority of one product over another. But when compared, for the shortest time of follow-up (D15), the platelet gel performed better, with greater reductions than the hydrocolloid in a short time like that. Histological analysis in the D0 and D90 of the treatment suggests that the GP acts to stimulate the regeneration of tissues (stroma together) and more definite form (diffuse distribution of vessels in the reticular dermis). The appearance of the closure of the injury is more consistent when compared with patients who used HC we observed the formation of a thin skin, fragile, observed in histological sections showed that a distribution of vessels in the papillary dermis. Histological sections confirmed... (Complete abstract click electronic access below)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP

Mortality and Recovery of Renal Function in Acute Kidney Injury Patients Treated with Prolonged Intermittent Hemodialysis Sessions Lasting 10 versus 6 Hours: Results of a Randomized Clinical Trial

Purpose. This trial aimed to compare mortality and recovery of renal function in acute kidney injury (AKI) patients treated with different durations of prolonged hemodialysis (PHD) sessions (6 h versus 10 h). Methodology. We included patients with sepsis-associated AKI, >18 years, who are in use of a norepinephrine (lower than 0.7 ucg/kg/min). Results. One hundred and ninety-four patients were treated with 531 sessions of PHD (G1=104 and G2=90 patients). The two groups were similar in age and SOFA. There was no significant difference in hypotension, hypokalemia, and anticoagulation during PHD sessions. The two groups showed differences in filter clotting, hypophosphatemia, and treatment discontinuation (12.3 versus 23.1%, p=0.002; 15.5 versus 25.8%, p=0.005; and 7.9 versus 15.6%, p=0.008, respectively). There was no difference in fluid balance (FB) before and after PHD sessions. Death and complete recovery of renal function were similar (81.3 versus 82.2%, p=0.87 and 21 versus 31.2%, p=0.7, respectively). At logistic regression, the positive FB before and after dialysis was identified as risk factor for death, while volume overload after three PHD sessions and predialysis creatinine were negatively associated with recovery of renal function in 28 days. Conclusion. There was no difference in the mortality and recovery of renal function of AKI patients submitted to different durations of PHD and sessions lasting 10 h presented higher filter clotting, hypophosphatemia, and treatment discontinuation. ISRCTN Registry number is ISRCTN33774458

The use of antimicrobials in septic patients with acute kidney injury

Abstract Sepsis is the most common cause of death in critically ill patients and it may be associated with multiorgan failure, including acute kidney injury (AKI). This situation can require acute renal support and increase mortality. Therefore, it is essential to administrate antimicrobials in dosis to achieve adequate serum levels, preventing overdosis and drug toxicity or underdosing and risk for resistance to antibiotics and higher mortality. To date, there aren't validated guidelines on antibiotic dosis adjustment in septic patients with AKI and the recommendations are extrapolated from studies conducted in non-critical patients with chronic kidney disease in end stage receiving chronic renal replacement therapy. This study aimed to review and discuss the complexity of that issue, considering the several factors related to the drugs removal: critically ill patient characteristics, antimicrobial properties and dialysis method